Comments for Fight Aging!

Comment on Removing the Pressure of Impending Death by Lord BW

Lord BW — Tue, 31 Dec 2024 20:35:08 +0000

"Happy" new digit on the calendar. And with each new digit, the doom of life creeps ever closer. People have to wish each other happy new years because new years are sad by default. Christmas with its beautiful lights is over, now the cold year starts. The humble reality is that there is one less year to live. Everyone knows this subconsciously but we try not to think about it. There is a voice on ones head that whispers "see this old man with his crooked back who is struggling to walk? Who looks like he hadn't had sex since the 1980s? He was once a healthy young man, just like you. And you will be like him in a few short decades' time." "New years' resolutions" are a coping mechanism. It is "now that I have one less year to live, I gotta change things!" - no, one should improve whenever possible. Not just when that digit on the calendar goes up by one.

Comment on Urolithin A Derivatives Targeting Mitophagy in Clinical Trials by JLH

JLH — Tue, 31 Dec 2024 13:55:45 +0000

I have looked at Amazentis' website. Basically. It is about Urolithins, with A being the most useful. The mystery is just what is VNA318 ?
I suspect a Urolithin A derivative.
It is patent protected and orally available so there must be something they have developed which is rather better than plain old Urolithin A and is patentable.

Time will shed light on this. In the meantime keep on with the pomegranate in quite large doses. ( minimal side effect profile )

Comment on Urolithin A Derivatives Targeting Mitophagy in Clinical Trials by Reason

Reason — Mon, 30 Dec 2024 19:49:50 +0000

In reply to Michael. @Michael: the other materials associated with Vandria, not so prominent on their website, but can be found out there.

Comment on The Dominance of Old Blood by John

John — Mon, 30 Dec 2024 19:17:59 +0000

@Maisa,
In fact, menstruation is often considered as a partial reason for the longevity difference between men and women.. partly due to generally lower iron levels, partly due to other factors. Example: https://pubmed.ncbi.nlm.nih.gov/17324494/

@Ken, Dr. William Keough
This article describes a Silicon Valley company that's doing this, and the supposed benefits. The founder recommends 6x a year at $6k a pop, which, yes, is absurdly expensive. (Although there are cheaper medical tourism options.)
Good to know there's interest in this, at least!
https://sfstandard.com/2024/10/05/plasma-exchange-longevity-treatment/

Comment on The Dominance of Old Blood by Dr. William Keough

Dr. William Keough — Mon, 30 Dec 2024 15:14:40 +0000

How frequently would a patient require TPE to experience a significant effect on ageing?

Comment on The Longevity Pyramid, a Prevention Viewpoint by Edward Greenberg

Edward Greenberg — Mon, 30 Dec 2024 15:07:50 +0000

I think it is a false dichotomy that longevity researchers *either* care about prevention (focusing on modest interventions like CR mimetics) *or* care about rejuvenation (with focus on biotechnologies like cell therapies, in vivo gene therapy, senolytics). I think it is truly a "yes and", that one naturally follows from the other: - The *focus* of traditional western medicine is largely treating recognizable diseases - Rejuvenation-oriented therapies work best (and sometimes *only* work at all) in early-stage "pre-disease" AKA "prevention" settings. As such, in order to most effectively develop biotechnologies of rejuvenation in people: 1) The R&D/medical community needs to care about intervening *before* a traditional disease has been diagnosed (e.g., based on biomarkers and subclinical pathology, AKA "prevention") 2) Credible biomarkers (e.g., inflammatory markers, epigenetic clock(s), senescent cell burden) need be aligned upon by researchers and regulators as surrogate endpoints for classical "clinical" endpoints (e.g., progression free survival, overall survival). 3) Biotechnologies of rejuvenation need to be tested in those "prevention" stages of disease, with early efficacy based on modulation of those biomarkers/subclinical pathological features

Comment on The Dominance of Old Blood by JL

JL — Mon, 30 Dec 2024 14:01:36 +0000

It seems like there is good data on the effectiveness of TPE and NBE for anti-aging. It is surprising that there are so few research groups or companies working in this very promising area. Why is this the case? Is this because there is no patentable product here that can return a lot of profit?

Comment on The Dominance of Old Blood by Maisa

Maisa — Mon, 30 Dec 2024 13:38:00 +0000

I don't see blood donation as something beneficial in this sense, only for men... I menstruate a considerable amount of blood every month and I don't see any benefits. Only low levels of iron and B12, which I replace with supplements.

Comment on Urolithin A Derivatives Targeting Mitophagy in Clinical Trials by Michael

Michael — Mon, 30 Dec 2024 13:22:03 +0000

What makes you think VNA-318 is an urolithin-A derivative?

Comment on Developing a Cell Model of Aging-Like Mitochondrial Mutational Damage by erasmus

erasmus — Mon, 30 Dec 2024 11:41:10 +0000

if all the mtDNA can successfully be relocated to the cell nucleus in MitoMouse, would the mouse be expected to live longer?